* Says new clinical trial data, presented at the second
Congress of the European Academy of Neurology, showed
non-inferiority of lacosamide (VIMPAT) monotherapy compared with
controlled-release carbamazepine among patients with newly or
recently diagnosed focal epilepsy
Source text: http://bit.ly/1slGMaJ
Further company coverage:
(Gdynia Newsroom)
Read more
No comments:
Post a Comment